Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer : results of a prospective randomized study by Słowik, Agnieszka J. et al.
O R I G I N A L  A R T I C L E  Cardiotoxicity prevention with ramipril in breast cancer 131
and chronic forms of anthracycline ‑induced 
cardiotoxicity (AIC), which is classified into 
early ‑onset (first year) and late ‑onset cardio‑
toxicity.6 Chronic AIC typically presents as ir‑
reversible myocardial dysfunction and heart 
failure (HF). The estimated incidence of HF 
ranges from 6.6% to 26%.7,8 An asymptomatic 
INTRODUCTION Breast cancer (BC) is the 
most common malignancy in women world‑
wide.1,2 The use of potentially cardiotoxic anth‑
racyclines, cytostatic agents introduced many 
years ago, still remains the cornerstone of BC 
therapy.3‑5 Most sources distinguish between 
acute (throughout anthracycline treatment) 
Correspondence to: 
Ewa Konduracka, MD, PhD, 
Institute of Cardiology, 
John Paul II Hospital, 
ul. Prądnicka 80, 31‑202 Kraków, 
Poland, phone: +48 12 614 22 18, 
email: ekonduracka@interia.eu
Received: November 11, 2019.
Revision accepted: 
January 27, 2020.
Published online: 
January 29, 2020.
Kardiol Pol. 2020; 78 (2): 131‑137
doi:10.33963/KP.15163
Copyright by the Author(s), 2020
ABSTRACT
BACKGROUND Anthracycline ‑induced cardiotoxicity (AIC) remains the main long ‑term irreversible side 
effect in malignancy survivors. Cardiotoxicity prevention is one of the most reasonable approaches.
AIMS In this prospective randomized open ‑label study, we aimed to verify whether ramipril protects 
from early ‑onset AIC in women with breast cancer (BC).
METHODS We analyzed data from 96 women (median age, 47 years) with BC after breast surgery, without 
significant cardiovascular diseases, who were eligible for adjuvant anthracyclines. They were randomized 
to a ramipril or control arm. Cardiotoxicity was estimated with repeat echocardiography and the measurement 
of troponin I and N ‑terminal fragment of the prohormone brain natriuretic peptide (NT ‑proBNP) levels 
over 1‑year follow ‑up. Anthracycline ‑induced cardiotoxicity was defined as a decrease in left ventricular 
ejection fraction (LVEF), elevated biomarker levels, and/or occurrence of heart failure (HF) or cardiac death.
RESULTS A decrease in LVEF above 10‑percent points occurred in 6.3% of ramipril patients and 18.5% 
of controls (P = 0.15). No cases of HF, cardiac death, or LVEF decline below 50% were reported. The percentage 
of patients with elevated NT ‑proBNP levels increased with time in controls (P = 0.003) and remained unchanged 
in the ramipril arm. At the end of follow ‑up, an increase in NT ‑proBNP levels was more common and decline 
was less common in the control than ramipril arm (P = 0.01). No significant differences in troponin levels 
were found between the study arms. Ramipril was well tolerated in normotensive women.
CONCLUSIONS In relatively young women with BC without serious comorbidities, who received 
anthracyclines, 1‑year treatment with ramipril exerts potentially protective effects on cardiotoxicity 
assessed with NT ‑proBNP levels.
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a dose ‑dense schedule, doxorubicin was admin‑
istered every 2 weeks. Patients also received 
taxoids, trastuzumab, hormone therapy, and 
radiotherapy, as appropriate.
The exclusion criteria were as follows: 1) ad‑
vanced BC and referral for induction chemo‑
therapy; 2) pregnancy and breastfeeding; 3) cur‑
rent treatment with ACEIs or angiotensin re‑
ceptor blockers; 4) contraindications to ACEI 
treatment; 5) diabetes, coronary artery dis‑
ease, hypertension (except mild hypertension: 
140–159/90–99 mm Hg; 6) refusal to partici‑
pate in the study; 7) history of chest radiother‑
apy, another malignancy or treatment with an‑
thracyclines; and 8) baseline LVEF on echocar‑
diography below 50% or elevated baseline car‑
diac troponin levels (≥0.01 µg/l) or N ‑terminal 
fragment of the prohormone brain natriuretic 
peptide (NT ‑proBNP) levels above 125 ng/ml.
It was a prospective single ‑center random‑
ized non–placebo ‑controlled open‑label study. 
Participants were randomized in a 1:1 ratio 
to a ramipril or control arm by means of a ded‑
icated software. We estimated that with a pow‑
er of 95% and a 2‑sided α level of 0.05, at least 
40 patients in each group were required.
Treatment with ramipril was started before 
chemotherapy and was continued for 1 year. 
The dose was slowly titrated, starting from 
2.5 mg and escalated every 7 to 14 days (depend‑
ing on tolerance) by 2.5 mg, until the planned 
maximum dose of 10 mg/d was achieved. In the 
case of ACEI intolerance, a lower best ‑tolerated 
dose was sustained. Patients in the ramipril 
arm continued with daily treatment for at least 
48 weeks. In the presence of medical indica‑
tions, daily doses higher than 10 mg were al‑
lowed. The control arm received standard ‑of‑
‑care treatment without any specified strategies 
of cardiotoxicity prevention (except treatment 
of hypertension without an ACEI as appropriate).
All participants underwent electrocardiogra‑
phy, echocardiography, and laboratory tests in‑
cluding the measurement of serum NT ‑proBNP 
and troponin I levels, according to the study 
protocol.
Echocardiography Complete echocardiogra‑
phy examination was performed at the E‑med 
outpatient cardiology clinic, using the VIVID 
S‑6 ECHO unit (GE Medical System, Boston, 
Massachusetts, United States), equipped with 
a multifrequency harmonic transducer (2.5–
4 MHz). Systolic function of the left ventricle 
was estimated with LVEF by means of the Simp‑
son method. The average values of 3 consecu‑
tive measurements were recorded. Most pa‑
tients were examined by the same operator (EK), 
blinded to patient allocation. Echocardiogra‑
phy was performed at baseline, after complet‑
ing anthracycline chemotherapy, as well as 24 
and 48 weeks (with a 4‑week deviation allowed) 
decline in left ventricular ejection fraction 
(LVEF) is observed in 9% to 50% of cases, mod‑
erately corresponding to the adopted definition 
of cardiotoxicity.8‑10
The risk factors for AIC include young age 
or age above 65 years, anthracycline cumula‑
tive dose (doxorubicin dose ≥250 mg/m2), use 
of other cardiotoxic drugs, previous or current 
chest radiotherapy, and history of cardiovas‑
cular comorbidities.11 As AIC may actually oc‑
cur at any dose as long as doxorubicin remains 
part of adjuvant therapy, preventive measures 
should be applied. However, no effective pre‑
ventive strategies for cardiotoxicity have been 
routinely implemented so far. Based on ear‑
ly trials concerning anthracyclines, the role 
of angiotensin ‑converting enzyme inhibitors 
(ACEIs) in cardiotoxicity prevention was hy‑
pothesized,12 but clinical data on this topic 
are scarce. A prophylactic intervention with 
an ACEI, although mentioned in Polish rec‑
ommendations, is not supported by sufficient 
data.13 On the other hand, the 2018 National 
Comprehensive Cancer Network guidelines for 
cancer survivorship do not propose any preven‑
tive pharmacologic strategy.14 Thus, the role of 
ACEIs in cardiotoxicity prevention in patients 
with BC without significant cardiovascular dis‑
ease remains undetermined.
The aim of this study was to evaluate the ef‑
ficacy of ramipril in the prevention of LVEF de‑
cline and an increase in the levels of laborato‑
ry biomarkers among women with low ‑risk BC 
treated with adjuvant anthracycline therapy in 
a 1‑year follow ‑up.
METHODS Consecutive women with stag‑
es I–III BC who underwent breast surgery and 
were referred for adjuvant anthracycline thera‑
py were eligible for the study. Patients received 
either an anthracycline + cyclophosphamide 
(AC) or fluorouracil + epirubicin + cyclophos‑
phamide (FEC) or epirubicin + cyclophospha‑
mide regimen (4–6 cycles). In the AC regimen, 
doxorubicin was administered at 60 mg/m2 
per chemotherapy cycle. In the FEC regimen, 
epirubicin was administered at  75  mg/m2 
or 100 mg/m2 every 3 weeks. In the case of 
WHAT’S NEW?
In women with breast cancer (BC) referred for cardiotoxic chemotherapy, 
a prophylactic intervention with an angiotensin ‑converting enzyme inhibitor 
is not supported by sufficient data. In our prospective study, treatment with 
ramipril was introduced shortly before chemotherapy in relatively young women 
with BC without significant cardiovascular disorders. At baseline and during 
and after chemotherapy with adjuvant anthracyclines, participants underwent 
repeated diagnostic workup with echocardiography as well as the measurement 
of NT ‑proBNP and troponin levels during a 1‑year follow ‑up. Ramipril showed 
potentially protective effects on cardiotoxicity, as assessed by NT ‑proBNP levels.
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variables and normal distribution, the t test was 
used. For non–Gaussian distribution, the Mann–
Whitney test was applied. Categorical variables 
were compared using the χ2 test, χ2 with Yates 
correction (as appropriate), or McNemar test. 
The analysis of variance and multivariate analy‑
sis of variance were used to compare the change 
over time for continuous dependent variables. 
Results from every patient who received at least 
1 chemotherapy cycle with doxorubicin were in‑
cluded in the final analysis.
RESULTS Between the years 2014 and 2017, 
we screened 450 women with a diagnosis of BC. 
At baseline, 348 women met the exclusion crite‑
ria. The remaining 102 women were randomized 
in a 1:1 ratio to the ramipril or control arm. After 
randomization, 4 participants did not keep vis‑
its and were excluded from the final analysis. In 
the ramipril arm, after a few days of treatment, 
1 woman discontinued the therapy due to weak‑
ness, without a significant drop in systolic blood 
pressure, while 1 patient died due to cancer pro‑
gression. The ramipril dose of 8.36 mg/d was 
the mean achieved dose, with 10 mg as the tar‑
get (higher doses were not considered as a tri‑
al intervention but as cardiac treatment). Three 
patients received ramipril at a dose of 20 mg/d 
due to hypertension.
Finally, 96 women (48 in the ramipril arm 
and 48 in the control arm), at a median age 
of 47 years (range, 38–54 years) completed all 
prespecified procedures. The main character‑
istics of the study population as well as data 
on cancer treatment are presented in TABLE 1 and 
in Supplementary material, Tables S1–S3.
Changes of left ventricular ejection fraction 
A decrease in LVEF was similar in both arms 
(5 women [11%] in the ramipril arm and 9 wom‑
en [18.5%] in the control arm; P = 0.16). How‑
ever, no cases of LVEF below 50% were report‑
ed. In the ITT analysis, there were no differenc‑
es between groups in terms of LVEF changes 
on repeated measurements (P = 0.18). Data are 
presented in FIGURE 1. At baseline and at the end 
of the study, no interaction with an introduced 
intervention with ramipril in terms of LVEF was 
observed (P = 0.34). There were no cases of HF 
or cardiac deaths.
Serum NT ‑proBNP levels There were no 
changes in the percentage of patients with ele‑
vated NT ‑proBNP levels over time in the ramipril 
arm (P = 0.42). However, an increase from 6.9% 
to 29.4% in the percentage of patients with 
 NT ‑proBNP levels of 125 pg/ml or higher was 
observed in the control arm (P = 0.003; FIGURE 2).
During follow ‑up, a steady increase over time 
in the percentage of patients with elevated NT‑
‑proBNP levels in the control arm was noted 
after enrollment. Cardiotoxicity was defined 
as a decrease in LVEF below 50% or more than 
10‑percent points from baseline.
Laboratory biomarkers Troponin levels were 
measured at baseline, after the first, middle (ie, 
depending on the regimen, after the second 
or third cycle), and last anthracycline chemo‑
therapy cycle, using an enzyme ‑linked immu‑
nosorbent assay. The reference value for tro‑
ponin I was lower than 0.01 µg/l. Cardiotoxici‑
ty was defined as an elevation of troponin lev‑
els (≥0.01 ng/ml).
The NT ‑proBNP level was assessed at base‑
line, after the first and last anthracycline cy‑
cle, and simultaneously with the last 2 echo‑
cardiography studies—after 24 and 48 weeks 
(±4 weeks). The NT ‑proBNP level was determined 
with an electrochemiluminescence immunoassay 
(Elecsys, Roche Diagnostic, France). The refer‑
ence value for healthy individuals younger than 
75 years was less than 125 pg/ml. Cardiotoxicity 
was defined as an elevation of NT ‑proBNP con‑
centrations (≥125 pg/ml).
Study endpoints Primary endpoints were 
an increase in the levels of troponin I or NT‑
‑proBNP (or both) above the upper limit of nor‑
mal and a decrease in LVEF below the lower lim‑
it of normal (as described above). The second‑
ary endpoint was HF or cardiac death (or both).
Safety procedures In all participants, arte‑
rial blood pressure and serum potassium levels 
were measured to monitor the safety of ramipril 
administration. All patients could contact a phy‑
sician throughout the study.
Ethical issues The study protocol complied 
with the Declaration of Helsinki and was ap‑
proved by the Ethics Committee of Jagiellonian 
University (no. KBET/208/B/2014). Each study 
participant provided written informed consent 
before enrollment. During the whole therapy, ef‑
fective contraception was applied in all partici‑
pants (acceptable for BC contraceptive methods). 
Statistical analysis The IMAGO PRO Ac‑
ademic 5 software pack (IBM SPSS Statistics 
25, Kraków, Poland) was used for statistical 
analysis. All statistical tests were 2‑sided with 
an α value of 0.05 (P ≤0.05 was considered sig‑
nificant). The statistical power was 0.95. Af‑
ter collection of data from patients, prelimi‑
nary intention ‑to ‑treat (ITT) and per ‑protocol 
analyses were performed. Results from the ITT 
analysis were presented unless described oth‑
erwise. Categorical variables were presented 
as percentages, while continuous variables, as 
median (interquartile range) or as mean and 
SD. The normality of distribution was checked 
with the Shapiro–Wilk test. For quantitative 
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On repeated measurements, we found no in‑
teraction with the intervention with ramipril 
(P = 0.43). At baseline and at the end of follow‑
‑up, there were no differences in the median 
serum NT ‑proBNP concentrations between 
the intervention and control groups: at base‑
line, 59.6 pg/ml (range, 38.25–84.6 pg/ml) and 
67.9 pg/ml (range, 42.2–97 pg/ml), respective‑
ly (P = 0.36), and at the end of the follow ‑up, 
81.9 pg/ml (range, 65.4–105.6 pg/ml) vs 89.2 
pg/ml (range, 61.1–174.4 pg/ml), respective‑
ly (P = 0.09). However, in the ramipril arm, 
the median NT ‑proBNP level at baseline did 
(P = 0.01). In the ramipril arm, the percentage 
of patients with elevated NT ‑proBNP levels re‑
mained the same at all time points (P = 0.3).
At the end of chemotherapy with anthracy‑
clines (P = 0.32) and at 6 months (P = 0.19), we 
observed no differences between the study arms 
in the percentage of patients with NT ‑proBNP de‑
cline, stabilization (±20% from baseline), and el‑
evation. A difference between the arms was not‑
ed at 12 months. More patients presented an in‑
crease (69% vs 41.9%) and fewer patients present‑
ed a decrease in NT ‑proBNP levels (3.4% vs 32.3%) 
in the control than in the ramipril arm (P = 0.01).
TABLE 1 Characteristics of the study population
Parameter Ramipril arm (n = 48) Control arm (n = 48) P value
Age, y, median (IQR) 45 (38–54) 45 (42–53) 0.45
BMI, kg/m2, median (IQR) 24.3 (23.05–28.48) 23.74 (21.11–25.56) 0.12
Baseline LVEF, %, median (IQR) 67 (65–70) 65 (64–69) 0.16
Baseline NT ‑proBNP, pg/ml, median (IQR) 59.6 (38.25–84.6) 67.9 (42.2–97) 0.36
Hemoglobin, g/l, mean (SD) 13.06 (0.95) 13.22 (0.97) 0.53
LDL ‑C, mmol/l, mean (SD) 3.10 (1.25) 2.90 (1.3) 0.08
Menopausal status, % Postmenopausal 27.3 34.5 0.36
Premenopausal 72.7 55.2
Weight gain, % 28.1 27.6 0.96
Smoking history, % 24.2 24.1 0.98
Family history of CVD, % 38 42 0.67
Prediabetes, % 6.1 10.3 0.54
Mild hypertensiona, % 12 13.8 0.88
SBP, mm Hg, median (IQR) 125 (110–135) 130 (110–135) 0.08
DBP, mm Hg, median (IQR) 79 (65–90) 80 (65–85) 0.18
SCORE, median (IQR) 0.92 (0.86–2.68) 0.8 (0.72–2.56) 0.95
POL ‑SCORE, median (IQR) 1. 32 (0.67–2.24) 1.42 (0.79–2.24) 0.52
Taxanes, % 48.5 58.6 0.43
Trastuzumab, % 15.2 34.5 0.08
Hormone therapy, % 69.7 89.7 0.05
Radiotherapy, % No radiotherapy 33.3 20.7 0.11
Right breast 51.5 41.4
Left breast 15.2 37.9
Total 64.5 78.6 0.74
GnRH analogue, % 18.2 10.3 0.38
Other antihypertensive 
drugs, %
β­‑Blockers 27 19 0.33
CCBs 5 6 0.97
Diuretics 3 5 0.96
a Only mild hypertension (stage 1) was allowed (SBP, 140–149 mm Hg; DBP, 90–99 mm Hg)
Abbreviations: BMI, body mass index; CCB, calcium channel blocker; CVD, cardiovascular disease; DBP, diastolic blood pressure; 
GnRH, gonadotropin ‑releasing hormone; IQR, interquartile range; LDL ‑C, low ‑density lipoprotein cholesterol; LVEF, left ventricular 
ejection fraction; NT ‑proBNP, N ‑terminal fragment of the prohormone brain natriuretic peptide; POL ‑SCORE, Systematic Coronary Risk 
Evaluation for Polish population; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation
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not change as compared with the 12th month 
of follow ‑up (59.6 pg/ml [range, 38.25–84.6 
pg/ml] vs  81.9  pg/ml (range, 65.4–105.6 
pg/ml); P = 0.44), but an increase was observed 
in the control arm (67.9 pg/ml [42.2–97 pg/ml] 
vs 89.2 pg/ml [61.1–174.4 pg/ml]; P = 0.002).
In the  whole study group (n = 96), an  in‑
crease of median NT ‑proBNP levels over time 
was observed: 65.45 pg/ml (range, 39.25–89.35 
pg/ml) at  baseline vs 105.10 pg/ml (range, 
42.3–174.5 pg/ml) at the end of the study (P = 0.007).
We stratified NT ‑proBNP results into 
9 groups (according to NT ‑proBNP class/cat‑
egory): 8 groups with an ascending threshold 
of 25 pg/ml, and the last group including the re‑
maining results (ie, >200 pg/ml). Next, we cal‑
culated the mean NT ‑proBNP class at differ‑
ent time points. Consistently with previous 
results, there was no effect of the  interven‑
tion on the NT ‑proBNP class on repeated mea‑
surements (P = 0.44), but significant changes 
of the class were observed over time (P = 0.03; 
FIGURE 3). An additional analysis was performed 
to verify whether the ramipril dose influenced 
the NT ‑proBNP level. However, the group treated 
with a low ACEI dose was very small (a few cas‑
es), and from a statistical point of view, it was 
not powered enough to show any differences.
Effect of other treatments and factors on 
NT ‑proBNP levels at 6 months There was no 
difference in the mean NT ‑proBNP concentra‑
tion between patients treated and not treated 
with radiotherapy. Similarly, taxoids and trastu‑
zumab had no significant effect on the mean 
NT ‑proBNP values at 24 weeks (P = 0.95 and 
P = 0.98, respectively).
Troponin An increase in troponin levels above 
the threshold value was reported in 6.9% of pa‑
tients in the control arm and 6.3% of those 
in the ramipril arm (P = 0.92). An increase in tro‑
ponin I concentrations always occurred after 
the last anthracycline infusion. Moreover, a ten‑
dency for a persistent rise in troponin levels on 
repeated testing in the control arm was noted, 
whereas in the intervention arm, it normalized 
at first follow ‑up visit. Eventually, the increase 
in troponin levels was reversible in all patients, 
and it was never associated with any changes on 
echocardiography or clinical symptoms during 
the 1‑year follow ‑up.
Safety We did not observe any severe ad‑
verse effects related to the ramipril treatment 
in the intervention group. Dry cough was re‑
ported by 3 patients. The dose escalation was 
objectively well tolerated, with no significant 
hypotension or tachycardia. Four normoten‑
sive patients did not reach the 10‑mg daily dose 
because of weakness or fear of hypotensive ef‑
fects despite maintained normal blood pressure.
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FIGURE 1 Comparison of changes in mean left ventricular ejection fraction (LVEF) values 
between rampiril and control arms during 1‑year follow ‑up: an intention ‑to ‑treat analysis. 
Vertical bars show 95% CI; P for interaction = 0.1816.
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FIGURE 2 Percentage of patients with N ‑terminal fragment of the prohormone brain 
natriuretic peptide (NT ‑proBNP) levels of 125 pg/ml or higher in the ramipril and control arms 
during 1‑year follow‑up: intention ‑to ‑treat analysis
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FIGURE 3 Comparison of changes in mean N ‑terminal fragment of the prohormone brain 
natriuretic peptide (NT ‑proBNP) levels between the ramipril and control arms during 1‑year 
follow ‑up: per ‑protocol analysis. Vertical bars show 95% CI; P for interaction = 0.2897.
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received an ACEI only as preventive treatment 
(merely 12.9% of women had mild hypertension 
without other significant cardiovascular disease).
Cardinale et al12,17 proved that ACEIs have 
a protective effect in a high ‑risk group defined 
as elevated troponin levels after high ‑dose che‑
motherapy. Earlier, the same authors showed 
that in patients with elevated troponin concen‑
trations, an intervention with ACEIs prevented 
deterioration of LVEF.18 In contrast, the recent 
ICOS ‑ONE trial (International CardioOncology 
Society ‑one), comparing prevention of primary 
vs troponin ‑induced AIC, did not demonstrate 
significant benefits of an early intervention with 
enalapril.19 However, the incidence of LVEF de‑
cline (<50% and ≥10% reduction) among patients 
with BC on standard cumulative doses of anthra‑
cycline was low (1.1%), similar to our study (0%). 
Nonetheless, the ICOS ‑ONE trial did not include 
the arm without any intervention, which made it 
impossible to verify the hypothesis of enalapril’s 
protective effect in this particular population. 
This issue was addressed in our trial. Moreover, 
routine laboratory biomarker testing (suggest‑
ed in the ICOS ‑ONE trial) was not implemented 
in clinical practice, mainly due to additional costs 
of cardiac biomarker measurement and a need 
for repeated blood collection.20 It is of interest 
that, in our study, chemotheraphy delays were 
observed more frequently in the ramipril arm, 
mostly due to neutropenia. However, the signif‑
icance of this finding is unknown.
Our study has several limitations. First, there 
was no active follow ‑up after 1 year. The study 
did not focus on late ‑onset cardiotoxicity, es‑
pecially late cardiovascular mortality. However, 
the follow ‑up (the second part extending beyond 
the first year as planned in the protocol) with‑
out any intervention or procedures for the as‑
sessment of HF development and overall sur‑
vival analysis will be continued.
Additionally, our study was performed in rel‑
atively young women without severe cardio‑
vascular disorders (except mild hypertension). 
As a consequence, our results cannot be applied 
to all women with BC. Further research focus‑
ing on the prevention of cardiotoxicity in a di‑
verse population of patients with BC is need‑
ed, because more aggressive BC phenotypes are 
common, especially in young women, who re‑
quire an intensive treatment. Recurrence risk in 
those phenotypes is higher, and further treat‑
ment, including chemotherapy, may be need‑
ed. Normal heart function is required for most 
treatments (chemotherapy, anti–human epider‑
mal growth receptor 2 therapy) that are offered 
in case of BC recurrence.
Another limitation of our study is the lack 
of placebo in the control arm. We also did not 
include subgroup analyses (eg, patients receiving 
trastuzumab because of a small number of pa‑
tients in this subgroup).
DISCUSSION In relatively young women with 
BC without concomitant cardiovascular disease, 
who received low cumulative doses of anthra‑
cycline (except women with mild hyperten‑
sion), ramipril did not prevent from LVEF de‑
cline in a 1‑year follow ‑up. These negative re‑
sults were undoubtedly influenced by the low 
prevalence of early ‑onset AIC on imaging (ac‑
cording to the adopted echocardiographic defi‑
nition of cardiotoxicity) in this “low ‑risk” group. 
However, to confirm that ACEIs have no effec‑
tiveness in this population, longer studies in‑
cluding patients with late ‑onset chronic cardio‑
toxicity are needed.
The  results of troponin measurements 
as a marker of AIC were inconclusive in our popu‑
lation. However, in the ramipril arm, in contrast 
with the control arm, we observed no increase in 
the percentage of participants with elevated NT‑
‑proBNP levels over time. This result may sug‑
gest certain preventive properties of ramipril. 
On the other hand, none of the available strate‑
gies for the prevention of cardiotoxicity are suf‑
ficiently sensitive to assess subclinical cardiotox‑
icity. All imaging modalities reveal only the al‑
ready existing clinical cardiac dysfunction, which 
in the context of anthracyclines is irreversible.
There is also no ideal biomarker in terms of 
AIC. In the available literature, NT ‑proBNP and 
troponins are the only accepted biomarkers, but 
they have their limitations.13,14 In the context 
of our own results, NT ‑proBNP was the most 
valuable marker. During the 1‑year follow ‑up, 
we only assessed the short ‑term preventive ef‑
fects of the ACEI, and we used changes in NT‑
‑proBNP concentrations as a surrogate endpoint 
because there are data to confirm that an in‑
crease in the levels of NT ‑proBNP can predict 
left ventricular dysfunction or failure as well 
as cardiac death. Therefore, especially patients 
with elevated NT ‑proBNP levels during chemo‑
therapy should be followed by cardio ‑oncologists 
on a long ‑term basis.
The role of ACEIs and β ‑blockers in anthra‑
cycline‑ and trastuzumab ‑induced cardiotox‑
icity is still debated. Most trials with ACEIs in 
AIC prevention focus on enalapril. We decided 
to use ramipril, because it belongs to the newer 
generation of ACEIs. However, Cernecka et al,15 
in a paper published 2 years after our trial was 
launched, revealed that ramipril was insufficient 
to restore proper cardiac function due to the lack 
of effect on a shift in myosin heavy chain.
A recent cohort study on 6542 elderly patients 
with BC retrospectively analyzed data on ACEI 
or β ‑blocker exposure. It showed the hazard ratio 
of 0.77 (95% CI, 0.62–0.95) for cardiotoxicity and 
all ‑cause mortality in favor of ACEI use.16 Howev‑
er, in this trial, ACEIs were used not as prevention 
but as treatment of cardiovascular disease, and 
the study population included elderly individu‑
als. On the contrary, most patients in our study 
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13 Opolski G, Krzakowski M, Szmit S, et al. Recommendations of National Team 
of Cardiologic and Oncologic Supervision on cardiologic safety of patients with 
breast cancer. The prevention and treatment of cardiovascular complications in 
breast cancer. The Task Force of National Consultants in Cardiology and Clinical 
Oncology for the elaboration of recommendations of cardiologic proceeding with 
patients with breast cancer. Kardiol Pol. 2011; 69: 520‑530.
14 Denlinger CS, Sanft T, Baker KS, et al. Survivorship, Version 2.2018, NCCN 
Clinical  Practice  Guidelines  in  Oncology.  J  Natl  Compr  Canc  Netw.  2018;  16: 
1216‑1247.
15 Cernecka H, Doka G, Srankova J, et al. Ramipril restores PPARβ/δ and PPARγ 
expressions and reduces cardiac NADPH oxidase but fails to restore cardiac func‑
tion  and  accompanied myosin  heavy  chain  ratio  shift  in  severe  anthracycline‑
‑induced cardiomyopathy in rat. Eur J Pharmacol. 2016; 791: 244‑253.
16 Wittayanukorn S, Qian J, Westrick SC, et al. Prevention of trastuzumab and 
anthracycline ‑induced cardiotoxicity using angiotensin ‑converting enzyme inhib‑
itors or β ‑blockers in older adults with breast cancer. Am J Clin Oncol. 2018; 41: 
909‑918.
17 Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction pre‑
dicted by early troponin I release after high ‑dose chemotherapy. J Am Coll Cardiol. 
2000; 36: 517‑522.
18 Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in 
cardiac risk stratification of cancer patients undergoing high ‑dose chemotherapy. 
Circulation. 2004; 109: 2749‑2754.
19 Cardinale D, Ciceri  F,  Latini R, et al. Anthracycline ‑induced cardiotoxicity: 
a multicenter randomised trial comparing two strategies for guiding prevention 
with enalapril: the International CardioOncology Society ‑one trial. Eur J Cancer. 
2018; 94: 126‑137.
20 Cardinale D, Biasillo G, Salvatici M, et al. Using biomarkers to predict and to 
prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn. 2017; 17: 245‑256.
Conclusion In relatively young women with 
BC without serious comorbidities, who received 
anthracycline therapy, 1‑year treatment with 
ramipril exerts a potentially protective effect 
on cardiotoxicity assessed with NT ‑proBNP. 
However, its efficacy in long ‑term prevention 
of AIC was not investigated in this study; there‑
fore, further research is needed. In the context of 
our own results, NT ‑proBNP was the most valu‑
able marker of cardiotoxicity. NT ‑proBNP test‑
ing seems reasonable even in a low ‑risk popula‑
tion receiving anthracyclines. In clinical prac‑
tice, patients with elevated NT ‑proBNP levels 
due to chemotherapy may need closer and long‑
‑term surveillance for AIC development. How‑
ever, the correlation between NT ‑proBNP levels 
and myocardial dysfunction should be further in‑
vestigated, especially in selected cancer patients.
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